New drug trial aims to tame rare clotting disorder
NCT ID NCT07584083
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the safety of an experimental drug called anifrolumab in 20 adults with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots and pregnancy complications. Participants receive weekly injections of the drug for up to 52 weeks, alongside their usual treatments. The main goal is to check for side effects, while also looking at how the drug affects the immune system and clotting markers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME (APS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Laiko General Hospital
RECRUITINGAthens, Greece, 11524, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental biologic aims to stop recurrent clots in antiphospholipid syndrome
- New drug RAY121 tested for Long-Term control of autoimmune diseases
- New drug targets immune overdrive in six rare diseases
- Could a cancer drug tame rare clotting disorder?
- New cell therapy hopes to tame tough autoimmune diseases
- Experimental cell therapy takes on lupus and other autoimmune diseases